Skip to main content
. 2019 Aug 31;22(6):870–877. doi: 10.1007/s12094-019-02197-6

Table 1.

TuFClot study metastatic breast cancer patient demographics

n (%)
Receptor status
 ER+, Her2− 26 (52)
 ER+, Her2+ 7 (14)
 ER−, Her2+ 9 (18)
 Triple negative 8 (16)
Metastatic sites
 Bone only 6 (12)
 Locally advanced 3 (6)
Single visceral site
 Liver 12 (24)
 Lung 12 (24)
 Brain 2 (4)
 Other 1 (2)
Multiple visceral sites (≥ 2) 14 (28)

Oestrogen receptor (ER) values were reported as a Modified Quick Score (QS) for all patients. A QS value of 0–2 was considered negative, 3–8 positive